Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

BioProcess International
September 20-23, 2027 as part of Biotech Week Boston
Hynes Convention CenterBoston, USA
Menu

Exclusive interviews from BioProcess International 2026

At BioProcess International 2026 our team met with a series of experts to discuss the future of biopharma research and pharma facilities, CMC lessons when it comes to bispecific molecules, and more.

The future is modular: Navigating flexibility in pharma facilities with Samir Gondalia

Hear from Samir Gondalia, Director of Business Development and Marketing at Hart Companies, about build-versus-outsource decisions in life science manufacturing, arguing that the key equation includes capital, risk, timeline, speed, and facility utilization rather than simply cost.

Why interdisciplinary science and AI will shape the future of biopharma research

This year, at Biotech Week Boston, we launched our very first BWB campus, creating a curated experience for the next generation of biopharma pioneers. We spoke to one of the keynote speakers, Marianna Tcherparkov, Director of Business Development, Frontage Laboratories Inc.Watch our conversation with her, where we discuss what critical skills the scientists of the future need to have to remain competitive in the next 5-10 years, the biggest challenges for aspiring scientists and why interdisciplinary science will be a core part of the industry.

Innovation vs standardization in drug development: Thomas Chattaway on the CMC roadmap

We met with Senior Life Science Consultant Thomas Chattaway, to discuss the tension between standardization and breakthrough innovation in pharma, why the industry is conservative on technology despite strong drug innovation, and insights from his CMC roadmap workshop on managing process changes. He highlights the growing range of drug modalities and stresses that foresight and early planning are key to a more efficient, patient-focused development process.

CMC lessons learned: What does it take to advance bispecific molecules to the clinic?

We spoke to Dr. Yun Bai, Executive Vice President of CMC, Santa Ana Bio, about her work on developing bispecific antibody products and leading the CMC and global clinical supply at Santa Ana Bio.Watch the interview, to learn about the balance between designing out the problem versus managing it through purification, the biggest challenges in early clinical trials and where companies should focus investments to build sustainable bispecific capabilities.